Decoding 6 Analyst Evaluations For Viridian Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided mixed ratings for Viridian Therapeutics (NASDAQ: VRDN) over the past three months, with a majority being bullish. The average 12-month price target has decreased by 6.05%, indicating a slight negative shift in sentiment. Key analysts have maintained or lowered their ratings and price targets, reflecting their response to recent developments.
August 15, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Viridian Therapeutics has received mixed ratings from analysts, with a majority being bullish. The average 12-month price target has decreased by 6.05%, indicating a slight negative shift in sentiment. Key analysts have maintained or lowered their ratings and price targets.
The mixed ratings and slight decrease in the average price target suggest a cautious outlook from analysts. While the majority are still bullish, the reduction in price targets indicates some concerns about the company's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100